Should bevacizumab be continued beyond progression in colorectal cancer?

Axel Grothey, Dirk Arnold, Lee M. Ellis

Research output: Contribution to journalReview articlepeer-review


Medical therapy for advanced colorectal cancer has seen signifi cant changes over the past decade. Most recently, molecular targeted agents such as antibodies against the epidermal growth factor receptor and the vascular endothelial growth factor (VEGF) have become integral components of treatment algorithms for this disease. The anti-VEGF antibody bevacizumab has been found to sig-nifi cantly prolong progression-free and overall survival when used (in conjunction with chemotherapy) as part of fi rst-line or second-line treatment. Recent preclinical and clinical data suggest that continuing bevacizumab beyond fi rst progression could be associated with a relevant clinical benefi t for patients with advanced colorectal cancer, but there are no data from randomized clinical trials on this issue. This review discusses the current state of the science and the rationale for and against continuing bevacizumab as part of antitumor therapy beyond progression of colorectal cancer.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalCurrent Colorectal Cancer Reports
Issue number3
StatePublished - Jul 2008

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology


Dive into the research topics of 'Should bevacizumab be continued beyond progression in colorectal cancer?'. Together they form a unique fingerprint.

Cite this